Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis
Authors' conclusion
CADM patients differ in disease onset, autoantibody profiles, joint and lung involvement. While laboratory and instrumental tests have not shown muscle involvement in CADM, many muscle biopsies have shown MHC-I overexpression.
Study context
- Population
- Patients of a DM cohort
- Participants
- 63 / 12 / 16
- Exposure
- Clinical amyopathic dermatomyositis (CADM) vs classic DM vs hypomyopathic DM (HDM)
- DMn = 63reference
- HDMn = 12
- CADMn = 16
- Outcome
- Features of CADM vs DM
Methodological detailsCox analysis
- Cox analysis
Main finding
As reported in the abstract
- Age at onset, years: CADM 45.5±17 vs DM 57±18
- p<0.05
- Age at diagnosis, years: CADM 46±17 vs DM 58±18
- p<0.05
- Anti-MDA5 positive: CADM 37.5% vs DM 4.8%
- p<0.05
- Anti-TIF1-γ positive: CADM 31.3% vs DM 6.3%
- p<0.05
- Arthritis: CADM 37.5% vs DM 12.6%
- p<0.05
- Interstitial lung disease (ILD): CADM 43.8% vs DM 15.9%
- p<0.05
Observational data: associations, not effects.
Further findings
Five-year survival · 5 years
Mortality predictors, overall cohort (Cox analysis)
| HR (CI) | ||
|---|---|---|
| ILD | 3.57 (1.11–11.5) | |
| Cancer | 3.67 (1.17–11.5) | |
| 0.050.21520Hazard ratio (log scale) |
| Outcome | HR (CI) | |
|---|---|---|
| Mortality predictors, overall cohort (Cox analysis)CADMvs DMNot a mortality predictor | 1.46 (0.33–6.68) | |
| 0.10.31310Hazard ratio (log scale) |
| Outcome | DM | HDM | CADM |
|---|---|---|---|
| Sarcolemma MHC-I expression on muscle biopsy | |||
| Biopsies available | 44 | 11 | 7 |
Sarcolemma MHC-I expression on muscle biopsy
- Similar sarcolemma MHC-I expression rates
Five-year survival · 5 years
- Comparable across groups
Original publication
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis. Clin Exp Rheumatol. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →